कृपया अन्य खोज का प्रयास करें
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California. NKGen Biotech, Inc. operates as a subsidiary of NKMAX Co., Ltd.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Michael L. Klowden | 77 | 2023 | Independent Director |
Anthony T. Reder | - | 2023 | Member of Scientific Advisory Board |
Craig Blackstone | - | 2023 | Member of Scientific Advisory Board |
Kathleen D. Scott | - | 2023 | Independent Director |
Evren Alici | - | - | Member of Scientific Advisory Board |
Ming Guo | - | 2023 | Member of Scientific Advisory Board |
Yong Ben | 49 | - | Scientific & Clinical Advisor |
Paul Y. Song | 58 | 2023 | CEO & Chairman |
Sangwoo Park | 54 | 2023 | Executive Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है